期刊文献+

9例先天性纯红细胞再生障碍性贫血患者临床分析并文献复习 被引量:2

The clinical analysis of 9 patients with Diamond-Blackfan anemia and the review of literatures
下载PDF
导出
摘要 目的:总结先天性纯红细胞再生障碍性贫血(DBA)的临床表现、实验室检查和治疗转归,进一步探讨DBA发病机制、诊断标准和治疗方法。方法:采用回顾性分析和文献复习的方法,对9例DBA患者进行研究。结果:9例DBA患者中,5例伴发先天畸形,4例身材矮小。初诊时Hb为(26~57)g/L[(43.3±10.7)g/L],MCV为80.3~112.5fl,网织红细胞比例均<1%,其中8例<0.5%,白细胞、血小板计数正常。66.7%患儿为O型血。全部病例骨髓检查红系增生低下0.5%~1.0%。7例患儿B淋巴细胞比例明显增高,6例患儿NK细胞比例降低或为正常低限。治疗以单纯激素口服为主,失访1例,余全部病例均对激素治疗完全有效,其中3例现已完全缓解。结论:本病为少见先天遗传性疾病,起病早,贫血重,多伴发身体畸形。诊断的主要指征是红细胞、Hb、网织红细胞比例减少及骨髓红系增生低下,而粒系及血小板增生正常;次要指征为婴幼儿期发病,并发先天畸形及身材矮小。本病国内临床诊断主要为排他性诊断。肾上腺皮质激素治疗起效快,治疗反应率高,治疗效果良好。 Objective:The clinical features,treatment and prognosis of a rare inherited pure red cell aplasia (DBA) were analyzed,and the related literature was reviewed.Method:Retrospective investigation of 9 patients with DBA in our hospital.Result:Five patients have physical abnormality and four with the height lower than 3% of the normal in 9 DBA cases. Hb levels were 26~57 g/L (43.3±10.7g/L),MCV was 80.3~112.5 fl,the percent of Ret was less than 1%,and WBC and platelet were normal. The 66.7% patients blood type was O type. The bone marrows of all patients were hyperplasia,especially in red blood cells,and seven patients had high B lymphocyte. The percents of NK cell were lower than normal . In glucocoticoid immunosuppressive therapy,but 1 patient lost ,the respond rate was 100% and the release rate was 33.3%.Conclusion:DBA is a rare inherited disease with the character of early onset,heavy anemia and frequently physical abnormality. The diagnosis of DBA was an exclusive diagnosis and DBA has a good response to glucocoticoid immunosuppressive therapy.
出处 《临床血液学杂志》 CAS 2010年第3期277-280,共4页 Journal of Clinical Hematology
关键词 贫血 再生障碍性 先天性 临床特点 诊断标准 激素治疗 inherited pure red cell aplasia clinical features diagnostic criterions glucocoticoid treatment
  • 相关文献

参考文献2

二级参考文献10

  • 1黄晓军,刘代红,许兰平,韩伟,江倩,陈育红,张耀臣,刘开彦,鲍立,陆道培.主要ABO血型不合异基因造血干细胞移植后纯红细胞再生障碍[J].中华血液学杂志,2005,26(9):548-550. 被引量:26
  • 2Gmur JP, Burger J, Schaffner A, et al. Pure red cell aplasia of long durationcomplicating major ABO-incompatible bone marrow transplantation. Blood, 1990, 75 ( 1 ):290-295.
  • 3Lee JH, Lee KH, Kim S, et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant, 2000, 25(2) :179-184.
  • 4Lee JH, Lee JH, Choi SJ, et al. Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. Br J Haematol, 2003, 120(4) :702-710.
  • 5Wemet D, Mayer G. Isoagglutinins following ABO-incompatible bone marrow transplantation. Vox Sang, 1992, 62(3) : 176-179.
  • 6Sieff C, Bicknell D. Caine G, et al. Changes in cell surface antigen expression during hemopoietic differentiation. Blood, 1982, 60 (3) : 703-713.
  • 7Cockerill KJ, Lyding J, Zander AR. Red cell aplasia due to host type isohemagglutinins with exuberant red cell progenitor production of donor type in an ABO-mismatched allogeneic bone marrow transplant recipient. Eur J Haematol, 1989, 43 ( 3 ) : 195-200.
  • 8Worel N, Greinix HT, Schneider B, et al. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion, 2000, 4(1(5):543-550.
  • 9Benjamin RJ, Connors JM, McGurk S, et al.Prolonged erythroid aplasia after major ABO-mismatched transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant, 1998, 4 (3) : 151-156.
  • 10Maschan AA, Skorobogatova EV, Balashov DN, et al. Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia. Bone Marrow Transplant, 2002, 30(6):405-407.

共引文献13

同被引文献35

  • 1Vlachos A, Bail S, Dahl N, et al. Diagnosing and treating Dia- mond Blackfan anaemia., results of an international clinical con- sensus conference[J]. Br J Haematol, 2008,142 (6) : 859-876.
  • 2Horos R, von Lindern M. Molecular mechanisms of pathology and treatment in Diamond Blackfan Anaemia[J]. Br J Haema- tol, 2012,159(5) : 514-527.
  • 3Orfali KA, Ohene-Abuakwa Y, Ball SE. Diamond Blackfan a- naemia in the UK: clinical and genetic heterogeneity[J]. Br J Haematol, 2004,125 (2) : 243-252.
  • 4Hamaguchi I, Ooka A, Brun A,et al. Gene transfer improves erythroid development in ribosomal protein S19-defieient Dia- mond-Blaekfan anemia[J]. Blood, 2002,100(8) ; 2724-2731.
  • 5Vlachos A,Ball S,Dahl N, et al. Diagnosing and treating Diamond Blackfan anaemia:results of an intema al clinical consensus confer- ence. Br J Haemato1,2008,142 ( 6 ) :859-876.
  • 6Ohene-Abuakwa Y, Orfali KA, Marius C, et al. Two-phase culture in Diamond Blackfan anemia: localization of erythroid defect. Blood, 2005,105 ( 2 ) : 838-846.
  • 7Miyake K, Utsugisawa T, Flygare J,et al. Ribosomal protein $19 de- ficiency leads to reduced proliferation and increased apoptosis but does not affect terminal crythroid differentiation in a cell line model of Diamond-Blackfan anemia. Stem Cells,2008,26(2) :323-329.
  • 8Jaako P,Flygare J,Olsson K,et al. Mice with ribosomal protein S19 deficiency develop bone marrow failure and symptoms like patients with Diamond-Blackfan anemia. Blood ,2011,118 (23) :6087-6096.
  • 9Hamaguchi I, Ooka A, Brun A, et al. Gene transfer improves ery- throid development in ribosomal protein S19-deficient Diamond- Blackfan anemia. Blood,2002,100 ( 8 ) :2724-2731.
  • 10Gazda HT, Grabowska A, Merida-Long LB, et at. Ribosomal protein $24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet,2006,79 (6) :1110-1118.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部